Healthcare Management Second Dupixent Phase 3 Eosinophilic Esophagitis Trial To Demonstrate Significant Disease… AIT News Desk Oct 25, 2021 Second Dupixent (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2…